ES2421885T3 - Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia - Google Patents

Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia

Info

Publication number
ES2421885T3
ES2421885T3 ES08021660T ES08021660T ES2421885T3 ES 2421885 T3 ES2421885 T3 ES 2421885T3 ES 08021660 T ES08021660 T ES 08021660T ES 08021660 T ES08021660 T ES 08021660T ES 2421885 T3 ES2421885 T3 ES 2421885T3
Authority
ES
Spain
Prior art keywords
polypeptides
antibodies
patients
procedure
specific detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08021660T
Other languages
English (en)
Inventor
Lars Komorowski
Christian Probst
Anthonina Janssen
Winfried Stoecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euroimmun Medizinische Labordiagnostika AG
Original Assignee
Euroimmun Medizinische Labordiagnostika AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2421885(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euroimmun Medizinische Labordiagnostika AG filed Critical Euroimmun Medizinische Labordiagnostika AG
Application granted granted Critical
Publication of ES2421885T3 publication Critical patent/ES2421885T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Proteína que comprende un primer polipéptido de OspC, caracterizada porque el primer polipéptido de OspC está unidoa través de un puente disulfuro con un segundo polipéptido de OspC, formándose el puente disulfuro por unión de unacisteína que no está alejada más de 100 posiciones de aminoácidos del extremo N-terminal del polipéptido de OspC,presentando el primer y el segundo polipéptido de OspC una identidad de aminoácidos de al menos el 70% con la SEC IDNº: 3, SEC ID Nº: 6 o SEC ID Nº: 9.
ES08021660T 2008-12-12 2008-12-12 Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia Active ES2421885T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08021660.9A EP2199303B1 (de) 2008-12-12 2008-12-12 Polypeptide und Verfahren zur spezifischen Detektion von Antikörpern bei Patienten mit einer Borrelieninfektion

Publications (1)

Publication Number Publication Date
ES2421885T3 true ES2421885T3 (es) 2013-09-06

Family

ID=40568393

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08021660T Active ES2421885T3 (es) 2008-12-12 2008-12-12 Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia

Country Status (4)

Country Link
US (2) US8163500B2 (es)
EP (1) EP2199303B1 (es)
ES (1) ES2421885T3 (es)
PL (1) PL2199303T3 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2959971A1 (de) 2014-06-27 2015-12-30 Euroimmun Medizinische Labordiagnostika AG Verfahren und Vorrichtung zur Überführung von Flüssigkeiten
WO2016049148A1 (en) 2014-09-24 2016-03-31 Wellstat Diagnostics, Llc Compositions and methods for te diagnosis of lyme disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0506868T4 (da) 1989-12-22 2004-04-26 Mikrogen Molekularbiol Entw Immunologisk aktive proteiner fra Borrelia burgdorferi, tilhørende testkits og vaccine
US5620862A (en) * 1993-11-24 1997-04-15 University Of Connecticut Methods for diagnosing early Lyme disease
IL118578A (en) 1995-06-07 2006-12-31 Connaught Lab Hybrid nucleic acid molecule for expression of lipoproteins
WO1997042221A1 (en) 1996-05-02 1997-11-13 Statens Seruminstitut Novel osp-c derived peptide fragments
AT405940B (de) * 1996-06-21 1999-12-27 Immuno Ag Verfahren zur gewinnung und reinigung von rekombinantem, nicht-lipidiertem osp-protein

Also Published As

Publication number Publication date
EP2199303B1 (de) 2013-06-05
US8431135B2 (en) 2013-04-30
US20120177680A1 (en) 2012-07-12
EP2199303A1 (de) 2010-06-23
US8163500B2 (en) 2012-04-24
PL2199303T3 (pl) 2013-11-29
US20100150964A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
AR123908A2 (es) Proteínas de fusión para tratar trastorno metabólicos
ES2545895T3 (es) Proteína de fusión anticancerígena
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
NO20063026L (no) Antistoffer
PE20100054A1 (es) Inmunoglobulina con dominio variable dual
EA201491049A1 (ru) Противораковый слитый белок
ES2531288T3 (es) Proteína de fusión anticancerígena
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
PE20120021A1 (es) Mutantes fgf21
PE20070033A1 (es) Concentrado de proteina y flujo acuoso que contiene carbohidratos solubles de agua
WO2007115837B1 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
EA201100071A1 (ru) Новые композиции и способы
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
EA201491277A1 (ru) Противораковый слитый белок
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
MX2013007872A (es) Proteina de fusion anticancer.
MX340772B (es) Medios y metodos para fabricar neurotoxina altamente pura.
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
WO2008105178A1 (ja) リポソーム用生体成分抵抗性増強剤及びこれにより修飾されたリポソーム
BR112013025975A2 (pt) proteína de fusão anticancerígena
MX2010010213A (es) Peptido parcial de lacritina.
ES2421885T3 (es) Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
BRPI0715331B8 (pt) polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon